Sugi Predict

Sugi Predict / Compounds / SCHEMBL2348013

SCHEMBL2348013

SCHEMBL2348013

c1cncc(-n2ccc3ccccc32)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BIRC5 O15392 1/20 0.53
▸ MAPT P10636 3/20 0.47
▸ CYP19A1 P11511 3/20 0.47
▸ CYP2A6 P11509 3/20 0.47
▸ CYP3A4 P08684 2/20 0.47
▸ CYP2E1 P05181 1/20 0.47
▸ CDC7 O00311 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ ROCK1 Q13464 1/20 0.46
▸ HTT P42858 2/20 0.43
▸ PRKD3 O94806 1/20 0.43
▸ PRKCG P05129 1/20 0.43
▸ PRKCB P05771 1/20 0.43
▸ PRKCA P17252 1/20 0.43
▸ PRKACA P17612 1/20 0.43
▸ PRKACG P22612 1/20 0.43
▸ PRKACB P22694 1/20 0.43
▸ PRKCH P24723 1/20 0.43
▸ PRKCI P41743 1/20 0.43
▸ PRKCE Q02156 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29725523 1.00 BIRC5 (0.53) BIRC5MAPTCYP19A1CYP2A6CYP3A4
SCHEMBL13166899 0.83 BIRC5 (0.55) BIRC5MAPTCYP19A1CDC7CDK2
SCHEMBL1131757 0.81 BIRC5 (0.61) BIRC5MAPTCYP19A1CDC7CDK2
SCHEMBL30774450 0.81 BIRC5 (0.61) BIRC5MAPTCYP19A1CDC7CDK2
SCHEMBL170890 0.80 BIRC5 (0.70) BIRC5MAPTCDC7CDK2ROCK1
SCHEMBL29475118 0.80 BIRC5 (0.70) BIRC5MAPTCDC7CDK2ROCK1
SCHEMBL6655119 0.79 CYP11B2 (0.51) CYP19A1CYP2A6CYP3A4CYP2E1
SCHEMBL6846114 0.79 HTR1D (0.48) MAPTCYP19A1
SCHEMBL4875437 0.78 MAPT (0.47) BIRC5MAPTCYP19A1CYP2A6CYP3A4
SCHEMBL17067754 0.78 ROCK1 (0.50) MAPTCYP19A1CYP2A6CYP3A4CYP2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112930346-A Novel compounds as NADPH oxidase inhibitors 金其尤泰克斯瑞士股份有限公司 2021-06-08 — — CN claimed
EP-0129051-B1 SUBSTITUTED INDOLES CIBA-GEIGY AG (CH) 1990-07-04 — — EP claimed
CN-112930346-A Novel compounds as NADPH oxidase inhibitors 金其尤泰克斯瑞士股份有限公司 2021-06-08 — — CN disclosed
EP-2664669-B1 TREATMENT OF PLURIPOTENT CELLS JANSSEN BIOTECH INC (US) 2017-12-27 — — EP disclosed
US-8697739-B2 Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof NOVARTIS AG (CH) 2014-04-15 — — US disclosed
US-8008491-B2 poly(adenosine 5'-diphosphate ribose) polymerase inhibitors such as 1-phenyl-2-(piperazin-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridine-3-carboxaldehyde, used in the treatment and/or prevention central nervous system and cardiovascular disorders AVENTIS PHARMACEUTICALS, INC. (US) 2011-08-30 — — US disclosed
US-7855203-B2 Indazolyl-substituted pyrroline compounds as kinase inhibitors ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2010-12-21 — — US disclosed
US-7855203-B2 Indazolyl-substituted pyrroline compounds as kinase inhibitors ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2010-12-21 — — US disclosed
US-20100240650-A1 SUBSTITUTED PYRROLINES AS KINASE INHIBITORS ZHANG HAN-CHENG 2010-09-23 — — US disclosed
US-20100240650-A1 SUBSTITUTED PYRROLINES AS KINASE INHIBITORS ZHANG HAN-CHENG 2010-09-23 — — US disclosed
US-7759380-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2010-07-20 — — US disclosed
EP-0674620-A1 TRYPTAMINE ANALOGUES AS 5-HT 1?-LIKE AGONISTS SMITHKLINE BEECHAM PLC (GB) 1995-10-04 — — EP disclosed
WO-1994014771-A1 TRYPTAMINE ANALOGUES AS 5-HT1-LIKE AGONISTS SMITHKLINE BEECHAM PLC (GB) 1994-07-07 — — WO disclosed
US-5324737-A Analgesics, antirheumatic and antiinflammatory agents, glaucoma STERLING WINTHROP INC. (US) 1994-06-28 — — US disclosed
US-5068234-A Analgesics, rheumatic diseases, antiinflammatory agents or antiglaucoma STERLING DRUG INC. (US) 1991-11-26 — — US disclosed
EP-0444451-A2 3-Arylcarbonyl-1H-indoles useful as therapeutic agents STERLING WINTHROP INC. (US) 1991-09-04 — — EP disclosed
US-4609733-A THROMBOXANE SYNTHETASE INHIBITORS CIBA-GEIGY CORPORATION (US) 1986-09-02 — — US disclosed
EP-0189004-A2 Process for the preparation of 3-substituted indoles and intermediates therefor CIBA-GEIGY AG (CH) 1986-07-30 — — EP disclosed
US-4536505-A THROMBOXANE SYNTHETASE INHIBITOR, ANTIISCHEMIC, ANTIARRHYTHMIA, ANTIINFLAMMATORY AND HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1985-08-20 — — US disclosed
EP-0126401-A1 Indole compounds CIBA-GEIGY AG (CH) 1984-11-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240650-A1 SUBSTITUTED PYRROLINES AS KINASE INHIBITORS PRKDC, MAP2K2, TTK BIRC5 1272/4885MAPT 2315/4885CYP19A1 4085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.